Contineum Therapeutics, Inc. Class A Common Stock (CTNM) financial statements and ratios from SEC XBRL: revenue $8.25M (TTM), net margin -727.4%, revenue growth 37.5% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $8.25M |
| Net Margin | -727.4% |
| Revenue Growth (YoY) | 37.5% |
| EPS Growth (YoY) | -82.5% |
| FCF Growth (YoY) | 78.0% |
| Price / Book | 2.69 |
| Price / Sales | 69.19 |
| FCF Yield | -16.1% |
| Altman Z-Score | 17.69 (safe) |
| Sector P/E (Healthcare) | 21.7 |
CTNM overview · CTNM earnings · CTNM KPIs · CTNM investor relations · CTNM ownership · CTNM peers · CTNM filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.